TY  - JOUR

T1  - DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

JO  - Journal of Clinical Oncology

PY  - 2021/02/20

AU  - Niazi T

AU  - Williams S

AU  - Davis ID

AU  - Stockler MR

AU  - Martin AJ

AU  - Bracken K

AU  - Roncolato F

AU  - Horvath L

AU  - Martin J

AU  - Lim TS

AU  - Hughes S et al

ED  - 

DO  - DOI: 10.1200/jco.2021.39.6_suppl.tps266

PB  - American Society of Clinical Oncology (ASCO)

VL  - 39

IS  - 6_suppl

SP  - TPS266

EP  - TPS266

Y2  - 2024/12/22

ER  -